Gharavi A E, Pierangeli S S, Gharavi E E, Hua T, Liu X W, Barker J H, Anderson G H, Harris E N
Department of Medicine, Louisiana State University, New Orleans, USA.
Lupus. 1998;7(5):341-6. doi: 10.1191/096120398678920190.
Immunization of mice with beta2glycoprotein 1 (beta2GP1) induces production of antiphospholipid (aPL) antibodies, which were shown to have thrombus enhancing properties in an experimental mouse model, indicating that these antibodies are thrombogenic in vivo. To determine whether the thrombogenic effect of murine antiphospholipid antibodies is due to their aPL or their anti-beta2GP1 activity, we injected mice with murine monoclonal anticardiolipin (aCL) and anti-beta2GP1 antibodies. Effects of these antibodies on thrombus formation, was evaluated utilizing a mouse model which enables kinetics of thrombus formation to be studied. The results of this study showed that the size of the thrombus in animals injected with murine aCL antibodies was larger than that in control groups. There was no difference in thrombus kinetics between anti-beta2GP1 injected mice and controls, suggesting that the thrombogenic effect of aPL antibodies is not related to their anti-beta2GP1 activity alone. Mice receiving monoclonal antibodies with both aCL and anti-beta2GP1 activity, also increase thrombus size when compared with controls. These data indicate that murine aCL, but not anti-beta2GP1, antibodies are thrombogenic in vivo.
用β2糖蛋白1（β2GP1）免疫小鼠可诱导抗磷脂（aPL）抗体的产生，在实验小鼠模型中已证明这些抗体具有增强血栓形成的特性，这表明这些抗体在体内具有致血栓性。为了确定鼠抗磷脂抗体的致血栓作用是由于其aPL还是抗β2GP1活性，我们给小鼠注射了鼠单克隆抗心磷脂（aCL）和抗β2GP1抗体。利用一个能够研究血栓形成动力学的小鼠模型评估了这些抗体对血栓形成的影响。这项研究的结果表明，注射鼠aCL抗体的动物体内血栓大小比对照组更大。注射抗β2GP1抗体的小鼠与对照组之间在血栓动力学方面没有差异，这表明aPL抗体的致血栓作用并非仅与其抗β2GP1活性相关。与对照组相比，同时接受具有aCL和抗β2GP1活性的单克隆抗体的小鼠，其血栓大小也会增加。这些数据表明，鼠aCL抗体而非抗β2GP1抗体在体内具有致血栓性。
